銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

Goldline Pharmaceutical’s ?11.61 crore IPO allotment status is expected to be finalised today, May 15, 2026. Investors can verify their allotment details via the official websites of BSE? and the issue’s registrar, Bigshare Services Private Limited.
Issue Type: Book Building IPO
Total Issue size: 27 lakh equity shares??
Fresh Issue: 27 lakh equity shares?
Price Band: ?41 to ?43 per share
Face Value:? ?10 each?
Lot Size: 3,000 shares
Minimum Investment: ?2,58,000 (6,000 shares)
Book Running Lead Managers: Cumulative Capital Private Limited
Registrar: ?Bigshare Services Private Limited
Listing: BSE SME
[May 14, 2026, 07:00 PM]
|
Category? |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
11.52 |
|
Non-Institutional Investors (NIIs) |
365.75 |
|
Retail Investors |
264.47 |
|
Total? |
211.41 |
According to media reports, the Grey Market Premium (GMP) of Goldline Pharmaceutical's unlisted shares is ?15 per share today.?
The Company will utilise the net proceeds from the Fresh Issue towards the following purposes:
Check out newly listed IPOs on BSE and NSE.
Established in 2004, Goldline Pharmaceuticals Limited specialises in pharmaceutical marketing across five primary segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness.
To ensure a reliable supply chain and a steady market presence, the company currently collaborates with 15 manufacturers and 8 distributors under contractual agreements.
As of the period ending December 31, 2025, the company achieved an operational revenue of ?21.40 crore. During the same period, Profit after Tax (PAT) was ?2.22 crore, with EBITDA of ?4.15 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.